Department of Cardiovascular Medicine, Beaumont Hospital Royal Oak, Royal Oak, MI, USA.
Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
Ann Med. 2021 Dec;53(1):2090-2098. doi: 10.1080/07853890.2021.2000633.
Type II diabetes mellitus (DM) is a proinflammatory process and a known risk factor for major adverse cardiac events (MACE). The same inflammatory markers may be present in prediabetes (pDM); however, the relationship between pDM by HbA1c and MACE is not well studied. We sought to see if pDM increases one's risk for MACE.
We retrospectively studied patients at Beaumont Health, Michigan between 2006 and 2020. We divided patients into groups (G1-G5) based on haemoglobin A1c (HbA1c) trends over the study period as follows: G1: pDM patients who remained pDM; G2: pDM who progressed into DM; G3: pDM who normalized their HbA1c; G4: patients who maintained a normal HbA1c; and G5: patients with HbA1c persistently in the DM range. We compared MACE between the groups by univariate and multivariate regression analyses.
A total of 119,271 patients were included in the study (G1: = 13,520, G2: = 6314, G3: = 1585, G4: = 15,018, G5: = 82,834). Pairwise comparison revealed a statistically significant increase in the odds of MACE in all groups compared to those with normal HbA1c values (G4; < .001). After adjusting for baseline characteristics, multivariate regression revealed elevated odds of MACE in patients with persistent pDM (G1; aOR = 1.087, = .002) and diabetes (G2/G5; aOR = 1.25 and aOR = 1.18, < .001) compared to individuals with normal HbA1c values.
Prediabetes is a risk factor for MACE. Normalization of HbA1c values appears to decrease the adjusted risk for MACE and should be the goal in patients with pDM.KEY MESSAGESPatients with prediabetes (pDM) are at increased risk for major cardiovascular events.Normalization of HbA1c in pDM patients may have a clinically significant benefit, in terms of lowering the MACE risk.Prediabetes patients who progress into diabetes mellitus may represent a particularly high-risk group.
2 型糖尿病(DM)是一种炎症过程,也是主要不良心脏事件(MACE)的已知危险因素。同样的炎症标志物可能存在于糖尿病前期(pDM)中;然而,pDM 按糖化血红蛋白(HbA1c)划分与 MACE 之间的关系尚未得到很好的研究。我们试图了解 pDM 是否会增加发生 MACE 的风险。
我们对密歇根州 Beaumont Health 的 2006 年至 2020 年间的患者进行了回顾性研究。我们根据研究期间的糖化血红蛋白(HbA1c)趋势将患者分为以下几组(G1-G5):G1:pDM 患者仍为 pDM;G2:pDM 进展为 DM;G3:pDM 糖化血红蛋白正常化;G4:保持 HbA1c 正常的患者;G5:HbA1c 持续处于 DM 范围内的患者。我们通过单变量和多变量回归分析比较了各组之间的 MACE。
共有 119271 名患者纳入研究(G1:=13520,G2:=6314,G3:=1585,G4:=15018,G5:=82834)。两两比较显示,与 HbA1c 值正常的患者相比,所有组发生 MACE 的几率均有统计学意义上的增加(G4;<0.001)。在调整基线特征后,多变量回归显示持续存在 pDM(G1;aOR=1.087,=0.002)和糖尿病(G2/G5;aOR=1.25 和 aOR=1.18,<0.001)的患者发生 MACE 的几率升高与 HbA1c 值正常的患者相比。
糖尿病前期是发生 MACE 的危险因素。糖化血红蛋白(HbA1c)值的正常化似乎降低了 MACE 的调整风险,并且应该是 pDM 患者的目标。
糖尿病前期患者(pDM)发生主要心血管事件的风险增加。pDM 患者的糖化血红蛋白(HbA1c)正常化可能具有显著的临床获益,可降低 MACE 风险。进展为糖尿病的 pDM 患者可能代表一个特别高风险的群体。